Page last updated: 2024-08-21

physcione and paclitaxel

physcione has been researched along with paclitaxel in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guo, H; Sun, D; Xiang, Z; Zhang, Y	1

Other Studies

1 other study(ies) available for physcione and paclitaxel

Article	Year
Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Emodin; Female; Gene Expression; Humans; Mice, SCID; Paclitaxel; Phosphogluconate Dehydrogenase; rac1 GTP-Binding Protein; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays	2019

Article

Year

Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:4

Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Emodin; Female; Gene Expression; Humans; Mice, SCID; Paclitaxel; Phosphogluconate Dehydrogenase; rac1 GTP-Binding Protein; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2019